AcquisitionOther
HEAT BIOLOGICS, INC. acquired Elusys Therapeutics, Inc.
Public deal record from 8-K. The source names the buyer and target, and terms are shown only when the filing or announcement discloses them.
Deal tape row
HEAT BIOLOGICS, INC. -> Elusys Therapeutics, Inc. · $350 million
The strategic acquisition of Elusys significantly expands the Company's role in the biodefense space, complementing NightHawk's RapidVax® platform, which is designed to target emerging biological threats.
Open source record (SEC) ↗